Difference between revisions of "Resource:9736d9b3-fbe1-45cf-a5d0-20e19038d394"
From The Embassy of Good Science
Marc.VanHoof (talk | contribs) |
|||
| Line 12: | Line 12: | ||
}} | }} | ||
{{Related To | {{Related To | ||
| − | |Related To Theme=Theme:Cbe88760-7f0e-4d6d-952b-b724bb0f375e | + | |Related To Theme=Theme:Cbe88760-7f0e-4d6d-952b-b724bb0f375e;Theme:540f8241-c354-4249-8b63-6bdc2e74bdf8;Theme:83f33f33-e9ba-4589-b450-92e3992a22db |
}} | }} | ||
{{Tags | {{Tags | ||
Revision as of 14:28, 24 August 2020
ResourcesCases
Guest Authorship, Mortality Reporting, and Integrity in Rofecoxib Studies
What is this about?
The study by Drs X and Y and the accompanying Editorial by Drs Z and Q regarding rofecoxib illustrate the recurring problem of discretionary or data-driven analysis[1] This is a facutal case.
- ↑ FitzGerald, Garret A. "Guest authorship, mortality reporting, and integrity in rofecoxib studies." JAMA 300.8 (2008): 900-906.
Why is this important?
Given the possibility of selective analysis based on observed data and the risk of positive results due to chance alone, it is critical to know in detail which analyses were prespecified and when the prespecification occurred[1].
- ↑ FitzGerald, Garret A. "Guest authorship, mortality reporting, and integrity in rofecoxib studies." JAMA 300.8 (2008): 900-906.
